Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

28 August 2026 · By · Wire by Fusion42

Published

28 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 28 August 2026 · Fusion42 review

The FDA has cleared Adicet Bio's IND application for ADI-212, a next-generation gene-edited CAR T cell therapy targeting metastatic castration-resistant prostate cancer. Phase 1 clinical trials are expected to begin enrollment in Q4 2026.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You have a new pathway open to trial a cutting-edge CAR T therapy using gene editing for prostate cancer, making the U.S. clinical market more accessible. Move quickly to engage with trial sites and regulatory consultants to position your therapy ahead of emerging competitors.

◆ Coverage

2 sources · 28 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearancecancer-therapycar-tgene-editingclinical-trials